Literature DB >> 36075963

The orphan receptor GPR88 controls impulsivity and is a risk factor for Attention-Deficit/Hyperactivity Disorder.

Sami Ben Hamida1,2,3, Sarojini M Sengupta1,2,4, Ellie Clarke1,2, Michael McNicholas1,2, Eleonora Moroncini1,2, Emmanuel Darcq1,2,5, Marina Ter-Stepanian6,7, Marie-Ève Fortier1, Natalie Grizenko1,2, Ridha Joober1,2,8,9, Brigitte L Kieffer10,11,12.   

Abstract

The neural orphan G protein coupled receptor GPR88 is predominant in the striatum and cortex of both rodents and humans, and considered a potential target for brain disorders. Previous studies have shown multiple behavioral phenotypes in Gpr88 knockout mice, and human genetic studies have reported association with psychosis. Here we tested the possibility that GPR88 contributes to Attention Deficit Hyperactivity Disorder (ADHD). In the mouse, we tested Gpr88 knockout mice in three behavioral paradigms, best translatable between rodents and humans, and found higher motor impulsivity and reduced attention together with the reported hyperactivity. Atomoxetine, a typical ADHD drug, reduced impulsivity in mutant mice. Conditional Gpr88 knockout mice in either D1R-type or D2R-type medium spiny neurons revealed distinct implications of the two receptor populations in waiting and stopping impulsivity. Thus, animal data demonstrate that deficient GPR88 activity causally promotes ADHD-like behaviors, and identify circuit mechanisms underlying GPR88-regulated impulsivity. In humans, we performed a family-based genetic study including 567 nuclear families with DSM-IV diagnosis of ADHD. There was a minor association for SNP rs2036212 with diagnosis, treatment response and cognition. A stronger association was found for SNP rs2809817 upon patient stratification, suggesting that the T allele is a risk factor when prenatal stress is involved. Human data therefore identify GPR88 variants associated with the disease, and highlight a potential role of life trajectories to modulate GPR88 function. Overall, animal and human data concur to suggest that GPR88 signaling should be considered a key factor for diagnostic and treatment of ADHD.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36075963     DOI: 10.1038/s41380-022-01738-w

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  60 in total

1.  Developmental and adult expression patterns of the G-protein-coupled receptor GPR88 in the rat: Establishment of a dual nuclear-cytoplasmic localization.

Authors:  Renaud Massart; Virginie Mignon; Jennifer Stanic; Paola Munoz-Tello; Jerôme A J Becker; Brigitte L Kieffer; Michèle Darmon; Pierre Sokoloff; Jorge Diaz
Journal:  J Comp Neurol       Date:  2016-03-16       Impact factor: 3.215

2.  Mice Lacking GPR88 Show Motor Deficit, Improved Spatial Learning, and Low Anxiety Reversed by Delta Opioid Antagonist.

Authors:  Aura C Meirsman; Julie Le Merrer; Lucie P Pellissier; Jorge Diaz; Daniel Clesse; Brigitte L Kieffer; Jérôme A J Becker
Journal:  Biol Psychiatry       Date:  2015-06-06       Impact factor: 13.382

3.  Lack of anticipatory behavior in Gpr88 knockout mice showed by automatized home cage phenotyping.

Authors:  G Maroteaux; T M Arefin; L-A Harsan; E Darcq; S Ben Hamida; B L Kieffer
Journal:  Genes Brain Behav       Date:  2018-04-19       Impact factor: 3.449

4.  Mapping GPR88-Venus illuminates a novel role for GPR88 in sensory processing.

Authors:  Aliza T Ehrlich; Meriem Semache; Julie Bailly; Stefan Wojcik; Tanzil M Arefin; Christine Colley; Christian Le Gouill; Florence Gross; Viktoriya Lukasheva; Mireille Hogue; Emmanuel Darcq; Laura-Adela Harsan; Michel Bouvier; Brigitte L Kieffer
Journal:  Brain Struct Funct       Date:  2017-11-06       Impact factor: 3.270

5.  Increased Alcohol Seeking in Mice Lacking Gpr88 Involves Dysfunctional Mesocorticolimbic Networks.

Authors:  Sami Ben Hamida; Sueli Mendonça-Netto; Tanzil Mahmud Arefin; Md Taufiq Nasseef; Laura-Joy Boulos; Michael McNicholas; Aliza Toby Ehrlich; Eleanor Clarke; Luc Moquin; Alain Gratton; Emmanuel Darcq; Laura Adela Harsan; Rafael Maldonado; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2018-02-09       Impact factor: 13.382

6.  Remodeling of Sensorimotor Brain Connectivity in Gpr88-Deficient Mice.

Authors:  Tanzil Mahmud Arefin; Anna E Mechling; Aura Carole Meirsman; Thomas Bienert; Neele Saskia Hübner; Hsu-Lei Lee; Sami Ben Hamida; Aliza Ehrlich; Dan Roquet; Jürgen Hennig; Dominik von Elverfeldt; Brigitte Lina Kieffer; Laura-Adela Harsan
Journal:  Brain Connect       Date:  2017-10

7.  Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake.

Authors:  Chunyang Jin; Ann M Decker; Viren H Makhijani; Joyce Besheer; Emmanuel Darcq; Brigitte L Kieffer; Rangan Maitra
Journal:  J Med Chem       Date:  2018-07-30       Impact factor: 7.446

8.  The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?

Authors:  Sheree F Logue; Steven M Grauer; Janet Paulsen; Radka Graf; Noel Taylor; M Amy Sung; Lynn Zhang; Zoë Hughes; Virginia L Pulito; Feng Liu; Sharon Rosenzweig-Lipson; Nicholas J Brandon; Karen L Marquis; Brian Bates; Mark Pausch
Journal:  Mol Cell Neurosci       Date:  2009-09-29       Impact factor: 4.314

9.  Impaired working memory, cognitive flexibility and reward processing in mice genetically lacking Gpr88: Evidence for a key role for Gpr88 in multiple cortico-striatal-thalamic circuits.

Authors:  David M Thomson; Rebecca L Openshaw; Emma J Mitchell; Marianna Kouskou; Mark J Millan; Clotilde Mannoury la Cour; Brian J Morris; Judith A Pratt
Journal:  Genes Brain Behav       Date:  2020-11-03       Impact factor: 3.449

10.  Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors.

Authors:  Albert Quintana; Elisenda Sanz; Wengang Wang; Granville P Storey; Ali D Güler; Matthew J Wanat; Bryan A Roller; Anna La Torre; Paul S Amieux; G Stanley McKnight; Nigel S Bamford; Richard D Palmiter
Journal:  Nat Neurosci       Date:  2012-10-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.